Related Programs

Lifestyle Changes May Help Prevent One-Third of All Cancers New Drug for Rare, Hard-to-Treat Cancers Attacking NHL Early Treating Recurrent NHL with Monoclonal Antibodies What is Non-Hodgkin's Lymphoma?

Lymphoma Lymphoma Treatment

Targeted Therapy for NHL

Summary & Participants

Doctors are using drugs that mimic the natural immune response to help fight non-Hodgkin's lymphoma. Learn how these new treatments work.

Medically Reviewed On: July 11, 2008

Webcast Transcript

JOHN LEONARD, MD: Antibodies are naturally made by our immune system to fight infections. So we have, circulating in our blood and throughout our body, proteins or antibodies, that bind to specific targets on infections. They're made by our immune system in response to infections.

ANNOUNCER: Beginning in the 1970s, scientists began looking for ways to use artificial antibodies to fight cancer by targeting proteins on the surface of cancerous cells. One hurdle was to find targets that were not too widely distributed throughout the body, on healthy cells. The type of cancers known as lymphomas had a clear advantage for this research.

JOHN HAINSWORTH, MD: Lymphomas have been for a long time recognized as a group of cancers that are perhaps more amenable to this because they do have specific surface proteins that, if not entirely specific to the lymphoma, at least are very limited to this one group of cells in the body.

ANNOUNCER: One of those surface proteins is called CD20. It's found in most B-cell lymphomas, which are the most common type in non-Hodgkin's lymphoma.

JOHN LEONARD, MD: CD20 is a molecule; it's a protein that's present on the surface of B-cell lymphomas cells. The role or the function of this particular protein in the lymphoma cell is not very clear. But it is evident that the vast majority of patients with the B-cell type of lymphoma—again, the most common, general type—have this target on their lymphoma cells. And, therefore, an antibody that can bind to, can stick to this target and have a variety of different effects on the cell through this target, could result in shrinkage of the lymphoma and, obviously, a benefit to the patient.

ANNOUNCER: The therapeutics used to target the CD20 protein are artificial, or monoclonal, antibodies. They come in two forms: "Naked," which are monoclonal antibodies alone, and monoclonal antibodies that carry a radioactive material.

SANDRA HORNING, MD: Currently, there are three products that are on the market that we consider anti-CD20 monoclonal antibodies. The first is rituximab, also known as Rituxan, which is a naked or unconjugated antibody. And this was the first anti-CD20 antibody that was approved. There are also two conjugated antibodies that have radioisotopes. So these are also known as radioimmunotherapy. Both of them use the anti-CD20 mechanism for targeting. Both of them deliver radiation. These products are known as ibritumomab tiuxetan or Zevalin, or tositumomab, which is known as Bexxar.

ANNOUNCER: Most of the clinical research on monoclonal antibodies in lymphoma has focused on the naked type. Key studies in the mid-1990s showed rituximab improved outcomes for many patients with advanced disease.

Page 1 of 2 Next Page >>